Renal cell carcinoma Cell Models for Research

Renal cell carcinoma (RCC) accounts for approximately 2-3% of all adult cancers worldwide, with an estimated 431,288 new cases and 179,368 deaths in 2020 (GLOBOCAN, WHO). The incidence has been rising steadily, partly due to increased incidental detection. The 5-year survival rate for localized RCC is around 93%, but for metastatic disease it drops to about 12% (NCI SEER). Major risk factors include smoking, obesity, hypertension, and inherited syndromes such as von Hippel-Lindau (VHL) disease. The high mortality in advanced stages underscores the urgent need for better therapeutic strategies and biomarkers.

RCC is a heterogeneous disease with distinct histological subtypes (clear cell, papillary, chromophobe) and well-characterized genetic alterations, making it an ideal model for studying tumor biology and drug response. The availability of large public datasets (TCGA, COSMIC) and established cell lines facilitates mechanistic studies. Key open questions include the role of metabolic reprogramming, immune evasion, and resistance to targeted therapies. Gene-edited cell models enable precise manipulation of specific mutations to dissect their functional impact.

RCC pathogenesis is driven by several key pathways:

• • VHL/HIF pathway: In clear cell RCC (ccRCC), loss of VHL leads to stabilization of HIF-1α and HIF-2α, promoting angiogenesis, glycolysis, and cell proliferation.
• • PI3K/AKT/mTOR pathway: Activation of this pathway promotes cell growth and survival, often due to mutations in PTEN, PIK3CA, or MTOR.
• • Chromatin remodeling: Mutations in genes such as PBRM1, SETD2, and BAP1 alter gene expression and genomic stability.
• • Metabolic reprogramming: RCC cells exhibit altered glutamine and glucose metabolism, supporting rapid proliferation.

Data from TCGA and COSMIC.

Key signaling networks deregulated in RCC include:

• • HIF/VEGF axis: HIF-1α and HIF-2α upregulate VEGF, PDGF, and other angiogenic factors.
• • PI3K/AKT/mTOR: Activation via loss of PTEN or mutation of MTOR.
• • Wnt/β-catenin: Aberrant activation promotes proliferation and invasion.
• • MAPK/ERK: Often activated in papillary RCC via MET mutations.
• • Immune checkpoint pathways: PD-L1 expression is frequently upregulated, contributing to immune evasion.

Organoids derived from patient tumors retain the genetic heterogeneity and 3D architecture, making them valuable for drug testing and personalized medicine approaches.

Animal models for RCC include:

• • Patient-derived xenografts (PDX): Implantation of patient tumor fragments into immunodeficient mice, preserving tumor heterogeneity.
• • Genetically engineered mouse models (GEMM): Conditional VHL knockout combined with other mutations (e.g., PBRM1, BAP1) recapitulates ccRCC.
• • Induced models: Use of carcinogens or orthotopic injection of cell lines to generate tumors.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise genetic modifications. For example, a VHL knockout in a VHL-wild-type RCC cell line can be used to study HIF pathway activation. Conversely, a knock-in of an activating MET mutation in a papillary RCC cell line can model oncogenic signaling. These models are essential for validating gene function and drug targets. Commercially available, sequence-verified gene-edited cell lines accelerate research by providing consistent and reproducible models, but it is important to select validated clones to avoid off-target effects.

Gene-edited cell lines are used to validate the role of specific genes in tumorigenesis. For example, knocking out PBRM1 in a VHL-deficient background can assess its contribution to chromatin remodeling and gene expression. Similarly, introducing a BAP1 mutation can study its effect on cell proliferation and apoptosis. These models help identify novel oncogenes and tumor suppressors.

Isogenic pairs (wild-type vs. knockout) are powerful tools for drug screening. For instance, a VHL knockout cell line can be used to test HIF inhibitors, while a MET knock-in line can screen for MET inhibitors. Resistance mechanisms can be studied by exposing cells to increasing drug concentrations and identifying genetic changes. Gene-edited models allow precise control of resistance-associated mutations.

CRISPR-based synthetic lethality screens can identify genes that are essential only in the context of specific mutations. For example, in VHL-deficient cells, targeting HIF-2α or its downstream effectors may be selectively lethal. Gene-edited cell lines with reporter constructs (e.g., PD-L1 promoter driving GFP) can be used to screen for modulators of immune checkpoint expression.